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Abstract
Background: Obesity in postmenopausal women is associated with increased breast cancer risk,
development of more aggressive tumors and resistance to certain anti-breast cancer treatments.
Some of these effects might be mediated by obesity hormone leptin, acting independently or
modulating other signaling pathways. Here we focused on the link between leptin and HER2. We
tested if HER2 and the leptin receptor (ObR) can be coexpressed in breast cancer cell models,
whether these two receptors can physically interact, and whether leptin can transactivate HER2.
Next, we studied if leptin/ObR can coexist with HER2 in breast cancer tissues, and if presence of
these two systems correlates with specific clinicopathological features.
Methods: Expression of ObR, HER2, phospo-HER2 was assessed by immonoblotting. Physical
interactions between ObR and HER2 were probed by immunoprecipitation and fluorescent
immunostaining. Expression of leptin and ObR in breast cancer tissues was detected by
immunohistochemistry (IHC). Associations among markers studied by IHC were evaluated using
Fisher's exact test for count data.
Results: HER2 and ObR were coexpressed in all studied breast cancer cell lines. In MCF-7 cells,
HER2 physically interacted with ObR and leptin treatment increased HER2 phosphorylation on Tyr
1248. In 59 breast cancers, the presence of leptin was correlated with ObR (the overall association
was about 93%). This result was confirmed both in HER2-positive and in HER2-negative subgroups.
The expression of leptin or ObR was numerically more frequent in larger (> 10 mm) tumors.
Conclusion: Coexpression of HER2 and the leptin/ObR system might contribute to enhanced
HER2 activity and reduced sensitivity to anti-HER2 treatments.
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Background
Recent epidemiological and clinical data confirmed that
obesity in postmenopausal women is associated with
increased breast cancer risk, development of more aggres-
sive breast tumors and resistance to certain anti-breast
cancer treatments [1-4]. The molecular mechanisms of
this link are not clear, but several studies in animal and
cellular models suggested that excess body weight could
promote breast cancer through increased production of an
adipocyte-derived hormone leptin [5-7]. The primary
function of leptin is to regulate energy balance and food
intake by acting in the brain, but the hormone also plays
an important role in peripheral organs, modulating fertil-
ity, lactation, and immune response [8,9]. Leptin levels in
humans correlate with adiposity and are usually higher in
females than in males [8].
Leptin action is mediated through the transmembrane
leptin receptor ObR [10]. The human ObR can be
expressed as at least four isoforms with different COOH-
terminal cytoplasmic domains [11]. The full (long) form
of ObR (ObRl) contains the extracellular, transmem-
brane, and intracellular domains [10]. Only ObRl has a
full signaling potential, while the short ObR isoforms
(ObRs) have diminished or abolished signaling activity
[12]. ObRl is highly expressed in the hypothalamus, how-
ever lower levels of ObRl have been identified in many
peripheral tissues [5,13-15]. The major pathways acti-
vated by ObRl are the classic cytokine JAK2/STAT3 path-
way, the Ras/ERK1/2 signaling cascade, and the PI-3K/
Akt/GSK3 growth/anti-apoptotic pathway [12].
Recently, leptin has been found to be involved in neoplas-
tic processes, especially in breast carcinogenesis [5-7,16].
Specifically, leptin can promote cancer cell growth and
transformation in vitro and in vivo, and increase cell sur-
vival in the presence of anti-cancer drugs [5,17]. The role
of leptin in breast cancer has been substantiated by the
fact breast tumors, but not normal mammary epithelium,
overexpress both leptin and ObR [18-20], and the leptin/
ObR system correlates with higher tumor grade and worse
prognosis [18,19]. In addition, intratumoral levels of
ObRl and ObRs and high levels of serum leptin were
found to correlate with poor prognosis [21].
Leptin may exert its activity not only through ObR, but
also through crosstalks with other signaling systems. For
instance, leptin affects the synthesis and/or function of
estrogen receptor alpha (ERα), vascular endothelial
growth factor (VEGF), and human epidermal growth fac-
tor receptor 2 (HER2) [5,6,22-25]. Leptin may also pro-
mote tumor cell survival in xenograft models via increased
expression of E-cadherin [17].
HER2 is a tyrosine kinase that is amplified in 25–30% of
breast tumors and its overexpression often correlates with
a more aggressive, metastatic phenotype and worse prog-
nosis [26,27]. Current therapies of HER2-positive tumors
include treatments with trastuzumab (Herceptin), a mon-
oclonal HER2 antibody, but resistance to this drug is a
common problem that ultimately leads to treatment fail-
ure [28]. The molecular basis of trastuzumab resistance
are still obscure, but there is evidence that increased acti-
vation of other growth factor signaling systems may con-
tribute to this process [28].
Preliminary data obtained in human embryonic kidney
HEK 293T cells engineered to coexpress HER2 and ObRs
or ObRl suggested that leptin, acting through either ObR
isoform, can rapidly induce HER2 phosphorylation and
activation of HER2 intracellular signaling [22]. Recent
data of Soma et al. suggested that in SK-BR-3 breast cancer
cells, leptin can transactivate HER2 through both the epi-
dermal growth factor receptor HER1 and JAK2 pathways
[29]. Thus, transactivation of HER2 by liganded ObR or
by HER1 might constitute an important mechanism of
HER2 resistance in breast cancer patients, especially those
expressing high levels of leptin and ObR in breast cancer
tissues. However, the existence of functional leptin/HER2
interactions in human breast cancer has not been
explored.
Consequently, using breast cancer cell lines naturally
expressing HER2 and ObR, we tested if HER2 and ObR
can physically interact and if exposure of cells to leptin
can transactivate HER2. To validate in vitro data, we stud-
ied whether the leptin/ObR system and HER2 can be
coexpressed in breast cancer biopsies and if coexpression
of these two systems is associated with specific clinico-
pathological features.
Methods
Patients and tissue samples
The expression of leptin, ObR, and other markers was
assessed in breast cancer samples. Tissue samples were
obtained from 59 women (31 HER2-positive and 28
HER2-negative) who underwent partial or total mastec-
tomy and lymph node dissection for primary breast can-
cer at the University and Public Hospitals in Verona
between January 1, 1992 and November 15, 2006 (Table.
1). All of the patients had a histologically confirmed diag-
nosis of breast cancer. Patients with a histological diagno-
sis of breast sarcomas and males with breast cancer were
excluded from the analysis. Clinical staging was applied
according to the sixth edition of the Union International
Contre le Cancer/American Joint Committee on Cancer
TNM classification manual [30]. All tissue samples were
anonymized and the local ethical committee approved
the study protocol.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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Pathological features
Diameter of the tumors was measured in millimeters,
their grading (G) was classified as standard G1, G2, G3;
node involvement was defined as positive (N ≥ 1) (cancer
cells found in one or more lymph nodes) or negative (N =
0) (absence of regional metastases). We further evaluated
lymphovascular invasion (LVI), classified as positive or
negative according to the presence or absence of tumor
cells in the lumens of lymphatic or blood vessels (Table.
1).
Biological features
In all cases, serial-step 5 μm sections were cut from paraf-
fin-embedded tissue samples and stained with hematoxy-
lin-eosin for histological examination. ERα and
progesterone receptor (PgR) status was determined by
immunohistochemistry (IHC). Tumors expressing at least
1% of cells positive for ERα or PgR were considered posi-
tive, according to recommendations of 10th  St Gallen
Conference on Primary Therapy of Early Breast Cancer
[31]. IHC staining for the replicative cell fraction was per-
formed using a Ki-67 monoclonal antibody (mAb)
(DAKO, Denmark). Ki-67 expression results were arbitrar-
ily classified as low (≤ 15% of stained cells), medium (16–
25%) or high (> 26%). HER2 levels were determined by
IHC using the HercepTest (DAKO). HER2 expression lev-
els obtained by IHC were scored as 0 (no staining), 1+
(faint incomplete membranous pattern), 2+ (moderate
complete membranous pattern) and 3+ (strong membra-
nous pattern). Samples with scores 0 and 1+ were consid-
ered HER2-negative and with the score 3+ were
considered HER2-positive. To confirm or exclude HER2
positivity, samples with a score 2+ were further evaluated
with fluorescence in situ hybridization (FISH) using Path-
Vysion assay (Abbott Diagnostics, Rome, Italy). The status
of p53 has not been assessed. The characteristics of
patients and tumors are summarized in Table. 1.
Detection of leptin and ObR in breast cancer biopsies
The expression of leptin and ObR was investigated by IHC
with specific Abs, as described by us before [18]. Briefly,
tissue sections were deparaffinized using a dry oven at
60°C overnight, then the slides were dewaxed in xylene
and rehydrated in graded series of ethanol. After rinsing in
PBS, endogenous peroxidase activity was inhibited by
incubation with 30% hydrogen peroxide, diluted in 100%
methanol for 30 min at 4°C. After three washes in PBS the
sections were incubated with 1.5% blocking serum for 1
h, then the sections were incubated for 3 h with primary
antibodies. For leptin staining, we used the A20 leptin
Table 1: Patient and tumor characteristics
Clinicopathological Features Patients n (%) Clinicopathological Features Patients n (%)
Menopausal status T
Postmenopausal 15 (25) TIS 3 (5)
Premenopausal 39 (66) pTx 1 (2)
Unknown 5 (9) pT1 19 (33)
Histotype pT2 22 (37)
Ductal invasive 45 (76) pT3 2 (3)
Lobular invasive 4 (7) pT4 12 (20)
Intraductal 3 (5) Diameter (mm)
Inflammatory 4 (7) ≤ 10 mm 9 (15)
Other 3 (5) > 10 mm 42 (71)
Grading Unknown 8 (14)
G1 7 (12)
G2 18 (31) N
G3 26 (44) pN1-3 20 (34)
Unknown 8 (13) pN4-10 9 (15)
Ki-67 pN > 10 4 (7)
0–15% 33 (56) Negative 19 (32)
16–25% 9 (15) Unknown 7 (12)
26–100% 14 (24) HER-2
Unknown 3 (5) Positive 31 (53)
ER/PgR Negative 28 (47)
ER+/PgR+ 38 (64)
ER-/PgR- 12 (20) LVI
ER+/PgR- 7 (12) Positive 27 (46)
ER-/PgR+ 1 (2) Negative 24 (41)
Unknown 1 (2) Unknown 8 (13)
G, differentiation grade; G1-3, low, moderate or intermediate, high grade. ER, estrogen receptor alpha; PgR, progesterone receptor; T, tumor size; 
pT1, 0–2 cm; pT2, 2–5 cm; pT3, > 5 cm; pT4, ulcerated or attached; Tis, carcinoma in situ; pTX, primary tumor of unknown pT; N, node status; LVI, 
lymphovascular invasion; n, number of cases.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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polyclonal Ab (pAb) (Santa Cruz Biotechnology, Santa
Cruz, USA) at 1:100 dilution; for ObR staining, the M18
ObR pAb (Santa Cruz Biotechnology) at 1:50 dilution
overnight at 4°C. The leptin and ObR antigens were
detected with avidin-biotin-peroxidase ABC staining sys-
tems (Santa Cruz Biotechnology). All slides were counter-
stained with Mayer's hematoxylin. Breast specimens
previously classified as positive for the expression of the
studied markers were used for control and protocol stand-
ardization. In negative controls, primary Abs were omit-
ted. Assessment of immunoreactivity was performed in at
least 10 different section fields by two independent evalu-
ators by light microscopy, and the mean percentage of
tumor cells displaying positive staining was scored. The
expression of leptin and ObR in cancer samples was clas-
sified using a four-point scale: 0, < 10% stained cells; 1+,
10–50% cells with weak staining; 2+, >50% cells with
weak staining; 3+, > 50% cells with strong staining.
Tumors with the score of at least 1+ were considered pos-
itive for the expression of leptin or ObR.
Cell culture and treatments
Breast cancer cell lines used in this study included MCF-7,
SK-BR-3, BT-474 and ZR-75-1 cells, all purchased from the
American Type Culture Collection (Rockville, MD, USA).
MCF-7 cells were grown in Dulbecco's modified Eagle's
medium (DMEM:F12) (Cellgro, Herndon, VA, USA) con-
taining 5% calf serum (CS) and 1% Penicillin/Streptomy-
cin (P/S) (Cellgro). SK-BR-3 cells were grown in DMEM
F12 containing 10% fetal bovine serum (FBS) and 1% P/
S. BT-474 cells were grown in DMEM:F12 containing 10%
FBS, 1% P/S and 0.01 μg/mL insulin. ZR-75-1 cells were
grown in RPMI-1640 (BioWhittaker, Walkersville, MD,
USA) containing 10% FBS, 1% P/S and 1 mM sodium
pyruvate (Cellgro).
For growth factor stimulation, the cells (4.5 to 6.0 × 105
cells/100 mm dish) were placed in phenol red-free serum-
free medium (SFM) [32] for 24 h and then stimulated
with different doses of leptin (Ob) (R&D systems, Minne-
apolis, MN, USA) or epidermal growth factor (EGF) (BD
Biosciences, Bedford, MA, USA) for 15 min.
Western blotting (WB) and immunoprecipitation (IP)
Total and phospho-HER2 levels were detected by Western
Blotting (WB) with Neu C-18 and p-Neu Tyr1248-R Abs
(Santa Cruz Biotechnology), respectively. Total protein
lysates were obtained as described before [32]. For WB or
IP of ObR, we used H-300 Ab (Santa Cruz Biotechnology)
recognizing a common domain within ObRl and ObRs
and suitable for detection of all ObR isoforms. For WB, we
routinely used 35–100 μg of total protein, while for IP,
500 μg of proteins were precipitated using protein A agar-
ose beads (Sigma-Aldrich, St. Louis, MO, USA). IP sam-
ples were precleared with protein A agarose for 4 h before
addition of primary Abs. Unrelated IgG was used as nega-
tive control for ObR Abs. Otherwise, all WB and IP proce-
dures and measurements of protein abundance followed
protocols described in detail before [32]. All WB and IP/
WB experiments were repeated at least 3 times.
HER2 and ObR detection by immunofluorescence/
deconvoluted microscopy
MCF-7 cells were plated in 2-well Permanox chamber
slide (Nunc, Rockester, NY, USA) at a concentration 9 ×
105 cells/well. Next day, the cultures were shifted in SFM
for 24 h and then treated with leptin 100 ng/mL for 15
min. Then the cells were washed three times with PBS,
fixed in 4% paraformaldehyde for 20 min at 4°C, washed
again and blocked with 7.5% BSA for 2 h at room temper-
ature. The expression of HER2 was detected using HER2
Neu C-18 Ab 1:100 (Santa Cruz) and donkey anti-rabbit
IgG-TRITC 1: 1000 (Santa Cruz); ObR was detected using
Ob-R F-18 Ab 1:50 (Santa Cruz) and donkey anti-goat IgG
FITC 1:1000 (Santa Cruz). The slides were covered with
Vectashield mounting medium containing DAPI (Vector
laboratories, IncBurligame, CA, USA) to allow visualiza-
tion of cells nuclei. The coexpression of HER2 and ObR
was assessed using Olympus IX81 deconvoluted micro-
scope and Slidebook software.
Elisa for phospho-HER2
MCF-7 cells were stimulated with 50, 100, 200, 500 ng/
mL leptin for 15 min, or were left untreated in SFM. Total
proteins were isolated as described for WB. Tyrosine phos-
phorylated HER2 (Tyr 1248) was measured using DuoSet
IC Human Phospho-ErbB2 Elisa kit (R&D Systems, Min-
neapolis, MN, USA), following manufacturers instruc-
tions. 350 μg of sample proteins and 150 ng of the
provided Tyr 1248 HER2 protein control were used for
measurements. The reading was done using Microplate
Autoreader Bio-Tek EL311.
Statistical analysis of data
Relationships among markers studied by IHC were evalu-
ated using Fisher's exact test for count data with a signifi-
cance level of 0.05 [33]. Statistical analyses were
performed using R for Windows software (R Development
Core Team. R: A language and environment for statistical
computing. R Foundation for Statistical Computing,
Vienna, Austria, 2007. ISBN 3-900051-07-0, URL http://
www.R-project.org). All Elisa and WB assays were done
data in triplicate and the results were evaluated using one-
way analysis of variance.
Results
ObR and HER2 are coexpressed in breast cancer cell lines
The results obtained in HEK 293T kidney cells engineered
to overexpress ObR and HER2 suggested that leptin can
transactivate HER2 [22]. Thus, we examined whether sim-BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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ilar interactions could occur in breast cancer cell models.
To this end, we tested ObRl and ObRs expression in four
different cell lines with varying levels of HER2: BT-474
and SK-BR-3 cells, known to express high levels of HER2,
and MCF-7 and ZR-75 cell lines characterized by moder-
ate HER2 expression (Figure. 1). The expression of the sig-
naling ObRl isoform (~190 kDa) as well as two short ObR
isoforms (~150 and 160 kDa) was confirmed in MCF-7
cells. Low levels of ObRl were also found in BT-474 cells,
while minimal expression of ObRl was detected in SK-BR-
3 and ZR-75 cells. All cell lines expressed different iso-
forms of ObRs (Figure. 2).
Leptin treatment transactivates HER2
To study whether leptin can transactivate HER2, we
focused on MCF-7 cell line as it expresses both HER2 and
high levels of ObRl and ObRs ([32] and Figure. 1). As
demonstrated by us and others before, MCF-7 cells
respond to 100–500 ng/mL leptin with the activation of
different intracellular pathways leading to cell prolifera-
tion and survival [32,34].
The acute stimulation (15 min) of MCF-7 cells with leptin
induced HER2 phosphorylation on Tyr1248. Leptin-
dependent activation of Tyr1248-HER2 was the strongest
with 200 ng/mL leptin, but HER2 was found phosphor-
ylated also with 100 and 500 ng/mL leptin (Figure. 2).
The highest doses of leptin (500 ng/mL) induced rapid
downregulation of HER2, most likely due to ligand-
dependent internalization [35]. Similar induction of
Tyr1248-HER2 was observed with EGF, a known activator
of this receptor [36] (Figure. 2). Like with leptin, the best
stimulation of HER2 was seen with the 200 ng/mL dose
and high EGF concentrations produced HER2 downregu-
lation. Lower doses of leptin or EGF (10, 25 and 50 ng/
mL) did not induce any HER2 response in MCF-7 cell
model (data not shown).
Activation of HER2 by leptin was also assessed independ-
ently using a specific phospho-HER2 Elisa kit. With this
methodology, we found that leptin at 100, 200, and 500
ng/mL induced HER2 phosphorylation on Tyr1248 by
135, 230, and 85%, respectively.
ObR and HER2 colocalize and coprecipitate in breast 
cancer cells
Next, we probed if HER2 and ObR can physically interact
in breast cancer cells. Using specific immunofluorescence
staining combined with confocal microscopy, we found
that HER2 colocalizes with ObR in MCF-7 cells (Figure.
3A). The colocalization was detected in 20 ± 0.7% of cells.
In addition, we found that HER2 can be detected in ObR
immunoprecipitates obtained from growing MCF-7 cells
(Figure. 3B).
The leptin/ObR system is coexpressed with HER2 in a large 
subgroup of breast cancers
The data obtained in breast cancer cell models prompted
us to investigate whether ObR isoforms together with
their ligand, leptin, can be coexpressed with HER2 in
human breast cancer. We analyzed the expression of lep-
tin and ObR by IHC in HER2-positive and HER2-negative
breast cancers characterized in Table. 1. This screening
demonstrated that both leptin and ObR can be expressed
in both HER2-positive and HER-2-negative tumors
(Table. 2, Figure. 4).
As noted in previous studies from our and other laborato-
ries, leptin and ObR tend to be coexpressed in different
cancers [18,19,37,38]. Similarly, the present analysis con-
firmed strong and significant associations between leptin
and ObR in all tumors (Table. 2 and Figure. 4); there were
only 4 cancers with a discordant result so that the overall
agreement was higher than 93%. The coexpression of lep-
Expression of HER2 and ObR in breast cancer cell lines Figure 1
Expression of HER2 and ObR in breast cancer cell 
lines. The expression of HER2 (185 kDa) and different iso-
forms of ObR (150–190 kDa, indicated by arrows) was 
detected in 50 μg of total protein lysates obtained from 
MCF-7, BT-474, SK-BR-3, and ZR-75 cell lines by WB with 
specific Abs, as described in Materials and Methods. The 
presence of a constitutively expressed enzyme GAPDH was 
assessed in the same blot as control of protein loading.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
Page 6 of 11
(page number not for citation purposes)
Transactivation of HER2 by leptin Figure 2
Transactivation of HER2 by leptin. MCF-7 cells were stimulated for 15 min with 100, 200, 500 ng/mL doses of leptin (Lep) 
or EGF. The expression of Tyr 1248 HER2 (p-HER2), total HER2 levels (HER2) was studied in 100 μg of total proteins by WB 
with specific Abs, as described in Materials and Methods. The levels of GAPDH in the same blots were assessed to control 
protein loading. The graph represents levels of Tyr 1248 HER2 relative to total HER2 under different stimuli. Bars represent 
SE.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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tin and ObR was confirmed both in HER2-positive and in
HER2-negative subgroups; the overall agreement was 97%
and 89% respectively (Table. 2).
The expression of leptin or ObR was, at least numerically,
associated with tumor size, being more frequent in large
(> 10 mm) tumors (Table. 3); however, owing to the lim-
ited sample size, this relationship was only marginally sig-
nificant for leptin (p = 0.061) and even less significant for
ObR (p = 0.137). The expression of leptin or ObR was not
associated with other considered variables (Table. 3).
Discussion
Obesity increases the risk of postmenopausal breast can-
cer by 30–50% [2]. Furthermore, excess body weight is
associated with poorer survival and increased recurrence
of cancer, regardless of menopausal status, after adjust-
ment for stage and treatment [2]. Because of the increas-
ing number of obese breast cancer patients, the
mechanism of this phenomenon is currently under thor-
ough investigation. Multiple studies implicated different
biologically active substances produced by adipose tissue
as possible contributing factors [4,5,7]. Steroid hormones,
e.g., estrogens, or growth factors, e.g., insulin-like growth
factor I, all of which are secreted by fat cells, are known to
promote breast cancer cell growth, transformation and
survival [39,40]. New evidence obtained in cellular and
animal breast cancer models suggests that leptin, the
major hormone produced by the fat tissue, can be mecha-
nistically involved in these neoplastic processes [6].
Although, in view of some inconsistent reports
[5,6,21,41,42], the impact of circulating leptin needs fur-
ther evaluation, one recent study correlated coexistence of
high systemic leptin concentrations and high intratu-
moral ObR mRNA levels with poor prognosis in breast
Physical interactions between ObR and HER2 Figure 3
Physical interactions between ObR and HER2. (A) Growing subconfluent cultures of MCF-7 cells were processed for 
HER2 (red staining) and ObR (green staining) immuofuorescence as described in Materials and Methods. Colocalization of 
HER2 and ObR was detected by merging (HER2+ObR) images (yellow staining). Cell nuclei were detected by DAPI (blue stain-
ing). (B) Total proteins from growing MCF-7 cells were immunoprecipitated with ObR Abs or control unrelated IgG, as 
described in Materials and Methods. The presence of HER2 in ObR and IgG IPs was detected by WB and is indicated by arrow. 
35 μg of total MCF-7 cell proteins were run on the same gel to control HER2 Ab specificity.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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cancer patients [21]. In addition, breast cancer cells them-
selves can synthesize leptin in response to obesity-related
stimuli [18,43,44]. It remains to be evaluated if the fre-
quent coexpression of leptin and ObR in breast tumors
[18-21,45] indeed reflects patient's adiposity.
As shown by many authors, leptin can exert its action not
only through ObR, but also through many other signaling
systems [5,6]. In the context of the most aggressive breast
cancer, it is important that leptin could crosstalk with
HER2 either through ObR, HER1, and JAK2 [22,29].
HER2 is a major marker of aggressive breast cancer and an
important pharmaceutical target [28,46]. HER2-targeted
therapies with trastuzumab improved survival of patients
with HER2 overexpressing metastatic breast cancer and
early-stage breast cancer. However, primary or treatment-
induced resistance to this drug often occurs [28,47]. The
mechanisms of this resistance seem to include increased
activation of other signaling systems, for instance, overex-
pression of IGF-I receptors, increased synthesis of EGF or
TGF-alpha, mutation of PTEN phosphatase resulting in
constitutive PI-3K activation [28,47]. Thus, targeting alter-
native signaling systems in HER2-positive tumors might
prove beneficial; indeed, clinical trials exploring such
options are underway [28,48].
However, the interaction between HER2 and the leptin
system has not been well explored in breast cancer. Here
we report that in breast cancer cell lines, endogenous
coexpression of HER2 and ObR is common, but cells
expressing very high levels of HER2 appear to express low
levels of ObR. In MCF-7 cells, which contain relatively
high levels of ObR [32] and moderate levels of HER2,
high physiological doses of leptin can induce HER2 tyro-
sine phosphorylation. Similar transactivation was recently
described in SK-BR-3 cells [29]. In the case of MCF-7 cells,
we show that leptin-dependent stimulation of HER2
Table 2: Associations between leptin and ObR in HER2-positive 
and HER2-negative breast cancer
ObR + ObR - p-value
N%N%
All tumors Leptin + 46 78.0 1 1.7 < 0.001
Leptin - 3 5.1 9 15.3
N%N%
HER2  Leptin + 23 74.2 0 0.0 < 0.001
positive Leptin - 1 3.2 7 22.6
HER2  Leptin + 23 82.1 1 3.6 0.045
negative Leptin - 2 7.1 2 7.1
The expression of leptin and ObR was assessed by IHC, as described 
in Materials and Methods. The percentage (%) and actual number (N) 
of tumors expressing combinations of leptin and ObR is given for all 
tumors as well as in HER2-positive and -negative subgroups. 
Associations between leptin and ObR in were evaluated using Fisher's 
exact test for count data.
Expression of the leptin/ObR system in HER2-positive and -negative breast cancer Figure 4
Expression of the leptin/ObR system in HER2-positive and -negative breast cancer. The expression of leptin and 
ObR was studied by IHC, as described in Materials and Methods in HER2-positive and HER-2-negative samples. The magnifica-
tion level is 40x. Arrows indicate the example areas of leptin and ObR staining.
HER2 positive
Lep positive
Lep negative
ObR positive
ObR negative
HER2 negative
ObR positive
ObR negative
Lep positive
Lep negativeBMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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could be facilitated by proximity or direct interaction of
HER2 and ObR, as demonstrated by colocalization and
coimmunoprecipitation experiments. The exact mecha-
nism of HER2 phosphorylation by liganded ObR is not
known, but one could speculate that intermediate cellular
tyrosine kinases, such as JAK2 (normally binding to acti-
vated ObRl) or src (possibly interacting with either ObRl
or ObRs), could be involved. On the other hand, in cells
expressing low ObRl levels, e.g., SK-BR-3 cells, leptin
appears to transactivate HER2 via HER1 and JAK2 path-
ways [29].
In this study, we evaluated whether HER2/ObR crosstalk
observed in cellular models could occur in human breast
cancer in vivo. We noted that the leptin/ObR system is
coexpressed with HER2 in a large fraction of breast can-
cers, which supports the possibility of intratumoral ObR/
HER2 interactions. Notably, the presence of leptin/ObR
Table 3: Associations between leptin, ObR, leptin/ObR and different clinicopathological parameters
Leptin ObR
N Positive (%) p-value Positive (%) p-value
Diameter (mm) 0.061 0.137
≤ 10 mm 9 55.6 66.7
> 10 mm 42 85.7 88.1
N > 0.5 0.242
N0 19 84.2 94.7
N+ (N > 0) 33 78.8 81.8
LVI > 0.5 0.473
Negative 24 79.2 87.5
Positive 27 77.8 77.8
Menopausal status > 0.5 > 0.5
Postmenopausal 15 80.0 86.7
Premenopausal 39 82.1 84.6
Histotype > 0.5 0.432
Other 3 66.7 66.7
Ductal (invasive) 45 80.0 84.4
Inflammatory 4 100.0 100.0
Intraductal 3 66.7 66.7
Lobular (invasive) 4 75.0 75.0
G 0.495 0.366
G1 7 85.7 100.0
G2 18 88.9 88.9
G3 26 73.1 76.9
Ki-67 > 0.5 > 0.5
0–15% 33 75.8 81.8
16–25% 9 88.9 88.9
26–100% 14 85.7 85.7
ER/PgR > 0.5 > 0.5
ER-/PgR- 12 75.0 83.3
ER-/PgR+ 1 100.0 100.0
ER+/PgR- 6 83.3 83.3
ER+/PgR+ 37 81.1 83.8
T 0.019 0.400
pT1 20 70.0 80.0
pT2 23 91.3 91.3
pT3 2 0.0 50.0
pT4 8 100.0 87.5
pTx 1 100.0 100.0
TIS 3 66.7 66.7
HER2 0.342 0.306
Negative 28 85.7 89.3
Positive 31 74.2 77.4
For each level of each clinicopathological variable, the total number (N) of patients is given together with the percentage of subjects positive for 
leptin or ObR expression. Abbreviations as in Tab. 2.BMC Cancer 2008, 8:305 http://www.biomedcentral.com/1471-2407/8/305
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was numerically more frequent in larger tumors. How-
ever, perhaps due to the relative small sample of tumors
analyzed, we were unable to detect any associations
between leptin/ObR and either tumor grade, ERα/PgR, or
metastasis, reported by different authors previously [18-
20].
The statistical analysis employed deserves some com-
ments. The Fisher's exact test is the dominant method for
making inferences from 2 × 2 tables where the number of
observations is small. The test assumes that both of the
margins in a 2 × 2 table are fixed by construction ("condi-
tional" test), but if an alternative process generates the
data, the test might not provide a correct coverage. None-
theless, the Fisher's exact test is often used, since in gen-
eral, it generates a conservative result. In our case no
margins of the 2 × 2 tables were fixed, so that an "uncon-
ditional" exact test would be more appropriate. To vali-
date our analysis, we performed such test, which gave, as
expected, a more significant result, in particular when ana-
lyzing the association between leptin and ObR in HER2-
negative tumors (p = 0.024 vs. p = 0.045 obtained using
the Fisher's exact test).
The finding that both leptin and ObR can be found not
only in HER2-positive but also in HER2-negative tumors
suggests that leptin/ObR and HER2 systems are controlled
by separate mechanisms. Interestingly, in our latest
screening of ~90 "triple-negative" tumors (lacking ERα,
PgR, and HER2 expression), we detected leptin and ObR
in most cases analyzed (manuscript in preparation, data
not shown). In this cellular context where hormonal and
traditional targeted therapy are not applicable, the leptin
system might constitute a new attractive target.
Conclusion
In summary, our results suggest the existence of crosstalk
between HER2 and the leptin system in breast cancer. This
notion implicates targeted anti-ObR therapies as possible
future therapeutic options, especially in tumors that
become resistant to targeted HER2 therapy. Such thera-
peutic approaches could be especially effective in patients
expressing high physiological levels of leptin (100–300
ng/mL), characteristic for the overweight and obese phe-
notype.
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